Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05641753 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cholesterol Lowering and Residual Risk in Diabetes, Type 1

Study acronym: CHORD1
StatusRecruiting
PhasePhase 4
Started2022-12-06
View on ClinicalTrials.gov ↗

Amendment history

2025-12-24
minor
2 amendments v3-v4
2 re-verifications since 2025-02-28, no change to tracked fields
2024-04-01
minor
Study Status, Contacts/Locations v2
Study sites3→4
2023-07-27
minor
Study Status v1
Primary completion date2027-01→2027-07-01
Completion date2027-01→2027-07-31
Start date2022-11-16→2022-12-06
2022-11-29
minor
Original filing
4,247 trials monitored
See 176 trials at risk
844 trials monitored
See 34 trials at risk
This is a prospective, interventional, cohort study, meaning that researchers will follow and observe a group of enrolled study participants over a period of time (one to two months) to gather information and record any developments of the outcomes in question. This study will recruit 125 participants with Type 1 Diabetes (T1D) to: 1. Analyze the effect of reducing the cholesterol levels in the blood on platelet function. (Platelets are small cells in the blood which help form blood clots to slow or stop bleeding and to help wounds heal 2. Analyze the effect of reducing the cholesterol levels in the blood on While Blood Cell (WBC) gene expression, (White Blood Cells are part of the body's immune system which help the body fight infection and other diseases) and 3. Analyze the effect of reducing the cholesterol levels in the blood on vascular or blood vessel function.
Trial Details
NCT Number NCT05641753
Lead Sponsor NYU Langone Health
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions Type 1 Diabetes
Enrollment 125 participants
Start Date 2022-12-06
Primary Completion 2027-07-01 (estimated)
Study Completion 2027-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-29